Venebio Group, LLC

?? Rare disease doesn’t mean rare impact. The FDA’s ARC program is paving the way for accelerated drug development by providing important tools for Learning and Education to ADvance and Empower Rare Disease Drug Developers: https://lnkd.in/eEW-xreB #LEADER3D

300 million people?worldwide live with a rare disease. Today, on Rare Disease Day 2025, we stand in solidarity with patients, families, and advocates who navigate the challenges of rare conditions every day. Rare diseases may be uncommon, but Venebio's dedication to fighting them is unwavering. Let's continue to push boundaries, foster new discoveries, and ensure no patient is left behind. Join the conversation, share your support, and learn more at?rarediseaseday.org #RareDiseaseDay #LifeSciences #HealthcareInnovation?

?????????? ???? ???????????????? ???????? ?????? ?????? Cardiovascular disease disproportionately affects women, yet research, testing, treatment, and funding have historically overlooked them. National Wear Red Day, observed annually on the first Friday of February, raises awareness about the need for heart health equity. Wearing red today is more than a symbol, it's a call to action for ???????????? ????????????????, ???????????? ??????????????????, ?????? ???????????? ???????????????? for everyone. Let’s take action and advocate for ?????????????????????? ????????-??????????. Learn more: hearttruth.gov

It is Day 2 at Cosmoprof North America in Miami at the Miami Beach Convention Center. Visit Preston Campbell, PhD and Ramez Labib at booth #260 to discuss how Venebio Group, LLC can support your brand and ensure it is in compliance with FDA MoCRA safety requirements. #CosmoprofNA #MoCRA #Cosmetics

Join Ramez Labib and Preston Campbell, PhD at Cosmoprof North America, the leading B2B beauty event in the Americas, next week! Meet us at ?????????? ?????? to explore our Cosmetics Membership Model and how we can provide comprehensive safety and regulatory support as your trusted partner in advancing your brand. #productsafety #cosmetics #MoCRA #Cosmoprofna

Venebio Group, LLC is a ChemFORWARD-approved assessor specializing in comprehensive chemical hazard assessments and raw material evaluations to qualify suppliers for SAFER? designation. Leveraging ChemFORWARD's GHS-based classification, rigorous?quality assurance, and cost-effective data-sharing model, Venebio supports clients in advancing chemical management and material intelligence while promoting industry-wide collaboration to transition to safer chemistry. #ChemicalSafety #DataCollaboration #HazardAssessment

Happy New Year from the Venebio Team! As we look back over the past year, we are grateful for our incredible clients, talented consultants, and trusted partners. Your support and collaboration have been the cornerstone of our success, and we couldn't have achieved all that we did in 2024 without you. We're excited for all that 2025 has in store! Stay tuned for updates on exciting changes and expanded capabilities as we continue to innovate and grow together. Wishing you and yours a happy, healthy, and prosperous New Year! Here's to new opportunities and continued success in 2025! #HappyNewYear #Gratitude #Growth #VenebioTeam #2025

Missed the opportunity to attend the recent 90-minuted accredited webinar on cosmetic ingredient assessments? The course is now available on demand for your convenience. Presented by Ramez Labib of Venebio Group, LLC and hosted by COBBLESTONE (previously CfPA - The Center for Professional Advancement), this advanced session explores: ? Core principles of toxicology and risk assessment ? Comprehensive analysis of global regulatory frameworks ? Information on the FDA's Modernization of Cosmetic Regulatory Act (MoCRA) Register now to access the course, anytime, anywhere. #CosmeticSafety #ProfessionalDevelopment #MoCRA

Last week, the FDA’s Center for Drug Evaluation and Research (CDER) unveiled the CDER Center for Real-World Evidence Innovation (CCRI)—a transformative initiative designed to harness real-world data (RWD) and real-world evidence (RWE) for smarter, faster regulatory decision-making. ???????? ???? ?????? ?????? ?????? ??????: Data from sources like electronic health records, medical claims, and disease registries. ??????: Insights derived from RWD, offering valuable perspectives on the safety and effectiveness of medical products in real-world settings. ?????? ???????? ?????????????? With advances in computing, emerging technologies, and epidemiology, CCRI will: ? Streamline drug development for unmet medical needs. ? Promote consistency and transparency in the use of RWD/RWE. ? Accelerate the delivery of effective, safe medicines to patients. #RealWordEvidence #DrugDevelopment #Innovation

MoCRA is in full swing and Venebio Group, LLC is ready to help you navigate this regulatory road with comprehensive end to end safety support. Contact Ramez Labib: [email protected] or (973) 964-5277 to discover how our expertise can support your business needs.